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The synthetic compound NO-1886 is a lipoprotein
lipase activator that lowers plasma triglycerides and
elevates high-density lipoprotein cholesterol (HDL-C).
Recently, the authors found that NO-1886 also had an ac-
tion of reducing plasma glucose in high-fat/high-sucrose
diet–induced diabetic rabbits. In the current study, we
investigated the effects of NO-1886 on insulin resistance
and ¯-cell function in rabbits. Our results showed that
high-fat/high-sucrose feeding increased plasma triglyc-
eride, free fatty acid (FFA), and glucose levels and de-
creased HDL-C level. This diet also induced insulin re-
sistance and impairment of acute insulin response to
glucose loading. Supplementing 1% NO-1886 into the
high-fat/high-sucrose diet resulted in decreased plasma
triglyceride,FFA,andglucoselevelsandincreasedHDL-C
level. The authors also found a clear increased glu-
cose clearance and a protected acute insulin response
to intravenous glucose loading by NO-1886 supplemen-
tation. These data suggest that NO-1886 suppresses
the elevation of blood glucose in rabbits induced by
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feeding a high-fat/high-sucrose diet, probably through
controlling lipid metabolism and improving insulin
resistance.
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Triglycerides
Chronichyperglycemiaandhyperlipidemiacanexertdele-
terious effects on ¯-cell function, respectively referred to as
glucotoxicity and lipotoxicity. Over time, both contribute to
the progressive deterioration of glucose homeostasis charac-
teristicoftype2diabetes[1–5].Bearingtheglucotoxicityand
lipotoxicity theories in mind, we recently established a high-
fat/high-sucrose diet–induced rabbit diabetes model, which is
useful for the studies of glucose and lipid metabolism [6, 7].
NO-1886, a lipoprotein lipase–promoting agent, was pri-
marilydevelopedasahypolipidemicagent.Administrationof
NO-1886 to experimental animals increased the postheparin
plasma low-density lipoprotein (LPL) activity and resulted in
a reduction in plasma triglyceride (TG) concentration with
a concomitant increase in high-density lipoprotein choles-
terol (HDL-C) concentration [8–14]. Signiﬁcant elevations
in plasma TG and very-low-density lipoprotein cholesterol
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(VLDL-C), and signiﬁcant reduction in HDL-C, appear to be
characteristic in diabetic patients [15–18]. Treatment of di-
abetes by low-energy diets, oral hypoglycemic agents, and
insulin therapy frequently is not sufﬁcient for perfect control
of lipid metabolism [16]. So, it is very important to develop
drugsthathavepotentialeffectsondiabeticdyslipidemia.Ac-
cording to the lipotoxicity theory, a drug, such as NO-1886,
that has a potential effect on hypertriglyceridemia may have
beneﬁcial actions in glucose metabolism. Recently, we did
ﬁnd that NO-1886 also had an action of reducing plasma glu-
coseinhigh-fat/high-sucrosediet–inducedrabbitdiabetes[7].
However,themechanismsbywhichNO-1886reducesplasma
glucosecannotbeclearlyexplainedfromtheresultsofourpre-
vious study without performing the glucose tolerance test or
insulin tolerance test in the animals. Therefore, in the current
study, we investigated the effects of NO-1886 on glucose, in-
sulin, and lipid proﬁles in high fat/high sucrose–induced mild
diabetic New Zealand White rabbits.
MATERIALS AND METHODS
Materials
Agent NO-1886 ([4-(4-Bromo-2-cyano-phenylcarbamoyl)-
benzyl]-phophonic acid diethyl ester; CAS 133208-93-2,
Lot. No. 1A77M) was synthesized in the New Drug Re-
search Laboratory of Otsuka Pharmaceutical Factory Inc.
(Tokushima, Japan). Sucrose was obtained from Liuzhou
Sugar Company (Guangxi, China) and lard was obtained
from Hengyang Meat Product Company (Hunan, China). All
otherchemicalsusedwerehigh-gradecommerciallyavailable
products.
Animal and Diets
All animal experiments were approved by the local animal
ethics committee of Nanhua University Medical College.
Male New Zealand White rabbits, weighing approximately
2 kg, were obtained from the Sheng Wan Experimental An-
imal Ranch (Shanghai, China). The animals were randomly
assigned into 4 groups: (A) normal group, which received
regular rabbit chow (Standard Laboratory Chow, Sheng Wan
Experimental Animal Ranch, Shanghai, China) for 28 weeks;
(B) normal NO-1886 group, which was fed regular rabbit
chow for the ﬁrst 4 weeks, then supplemented with 1.0%
NO-1886 for the remaining 24 weeks; (C) sucrose group,
which was fed high-fat/high- sucrose chow (incorporating
10% lard and 37% sucrose into the standard laboratory chow,
prepared in our institute [6]) for 28 weeks; (D) sucrose
NO-1886 group, which was fed high-fat/high-sucrose chow
for the ﬁrst 4 weeks, then supplemented with 1.0% NO-1886
for the remaining 24 weeks. Every group had 12 rabbits. The
rabbits were maintained in a 12-hour light-dark cycle at a
constant temperature of 23±C§2±C. The animals were fed at
9 AM, given an amount of 35 g/kg/day, and given free access
to tap water. Food consumption was measured daily and the
treated rabbits were trained to consume completely the whole
allotted portion of the food containing NO-1886 within an
hour. At the end of the experimental period, the animals
were killed by exsanguinations under sodium pentobarbital
anesthesia. The abdominal fat was removed and weighed.
Metabolic Measurements
Body weights were measured at the time points as indi-
cated. Blood samples for fasting glucose, insulin, and lipid
measurements were withdrawn from auricular veins at weeks
0, 4, 8, 13, 18, 23, and 28 after fasting overnight, kept at room
temperature for 30 minutes, and then centrifuged for 10 min-
utes, at 500 £ g (Beckman GPR, Palo Alto, CA). The serum
wasthencollectedandfrozenat¡20±Cuntilassayed.Glucose
tolerance test was performed on conscious animals following
an overnight fast by intravenous administration of glucose
(2g/Kg).Thebloodsamplesformeasurementsofglucoseand
insulin were withdrawn at 0, 5, 15, 30, 60, and 120 minutes.
The insulin tolerance test was done on fed conscious rabbits.
Human recombinant insulin (Shanghai Biochemistry factory,
Shanghai, China; 0.75 units/kg body weight) was injected in-
traperitoneally to the animals after appropriate dilution with
saline. The blood samples were withdrawn at 0, 15, 30, and
60 minutes after insulin administration served for determina-
tion of glucose.
Analytical Methods
Serum HDL-C (HDL-C Test Kit, Shanghai Rongsheng
BiotechInc.),triglycerides(TGTestKit,ShanghaiRongsheng
Biotech Inc.), free fatty acids (FFA Test Kit, Shanghai
Rongsheng Biotech Inc.), and glucose (glucose oxidase–
peroxidase method, Shanghai Rongsheng Biotech Inc.) were
determined by commercially enzymatic methods. Insulin was
determined by conventional radioimmunoassay, with the use
of Insulin Radioimmunology kit (Beijing Institute of Atomic
Research, Beijing, China).
Statistical Analysis
Values are reported as mean§SD. Comparisons between
groups were analyzed for statistical signiﬁcance using the
1-way analysis of variance, followed by the Dunnett’s test
multiple comparisons. P values less than .05 were considered
signiﬁcant.NO-1886 IMPROVES GLUCOSE AND LIPID METABOLISM 29
FIGURE 1
Accumulation of abdominal fat in the rabbits. The amount of
abdominal fat was signiﬁcantly higher in the rabbits of
group C than in the other 3 groups. Signiﬁcance: ¤P <: 05
versus group A, group B, and group D. n D 5–7.
RESULTS
Body Weight and Abdominal Fat
The mean body weight in animals of group C was the
highest,thoughitwasnotsigniﬁcantlydifferentfromtheother
3 groups during the experimental term of 28 weeks, but the
amountofabdominalfatwassigniﬁcantlyhigherintherabbits
of group C than in the other 3 groups (Figure 1). This is a
conﬁrmation for a previous study that had shown that NO-
1886 suppressed fat accumulation in rats fed a high-fat diet
[11].
FIGURE 2
Time course of serum triglyceride levels after NO-1886 administration. The increase of serum triglyceride group D was inhibited
by supplementing 1% NO-1886 into the high-fat/high-sucrose diets. Signiﬁcance: ¤P <: 05 versus group A. n D 5–12.
Effects of NO-1886 on Lipid Metabolism
Feedinghigh-fat/high-sucrosedietselevatedserumTGand
free fatty acid (FFA) levels. However, the increase of serum
TG and FFAs in group D was inhibited by supplementing 1%
NO-1886 into the high-fat/high-sucrose diets (Figures 2 and
3). This action of NO-1886 on blood FFAs was a new ﬁnding.
Administration of NO-1886 signiﬁcantly increased serum
HDL-C levels in normal (group B) and high fat/high sucrose–
fed NO-1886–supplemented (group D) rabbits (Figure 4).
Effects of NO-1886 on Fasting Blood Glucose
FastingbloodglucoselevelinrabbitsfromgroupDwasthe
highest (though it did not reach the signiﬁcant level) among
4 groups by the ﬁrst 4 weeks of high-fat/high-sucrose feed-
ing. However, the increase of glucose level in group D was
inhibitedbysupplementing1%NO-1886atthe8thweektime
point(4weeksafterstartofNO-1886administration).Fasting
blood glucose level in rabbits from group D was signiﬁcantly
lowerthaninrabbitsfromgroupCatthe23rdand28thweeks
(Figure 5).
There were no signiﬁcant differences in fasting serum in-
sulinlevelsamongthe4groupsduringtheexperimentalperiod
(data not shown).
Glucose Tolerance and Insulin Response
to Glucose Injection
Figure 6 shows blood glucose and insulin during in-
travenous glucose tolerance test (IVGTT) carried out in
overnight-fasted rabbits. There were no differences in blood30 W. YIN ET AL.
FIGURE 3
Effect of NO-1886 administration on serum FFA levels. Feeding high-fat/high-sucrose diets elevated plasma FFA levels. The
supplementing 1% NO-1886 inhibited the increase of FFAs in group D. Signiﬁcance:
¤P <: 05 versus group A. n D 10–12.
glucose (Figure 6A) and insulin (not shown) among 4 groups
during IVGTT carried out at week 0. However, blood glucose
wassigniﬁcantlyhigherinrabbitsfromgroupCversustherab-
bits from the other 3 groups at all time points, except at time
5 minutes, investigated after the glucose injection at week 13
FIGURE 4
Time course of serum HDLc levels after NO-1886 administration. NO-1886 signiﬁcantly increased serum HDL-C levels
in normal (group B) and high fat/high sucrose–fed NO-1886–supplemented (group D) rabbits. Signiﬁcance:
¤P <: 05 versus group A. n D 5–12.
(Figure6B)andatweek28(notshown).Aftertheintravenous
glucose administration, serum insulin at time point 15 min-
utes (Figure 6C) increased to a higher extent in the group B
and group D rabbits than the rabbits in group A; but in the
rabbits of group C, plasma insulin at time point 15 minutesNO-1886 IMPROVES GLUCOSE AND LIPID METABOLISM 31
FIGURE 5
Time course of blood glucose levels after NO-1886 administration. The increase of glucose level induced by high-fat
high-sucrose diet in group D was inhibited by supplementing 1% NO-1886 (4 weeks after start of NO-1886 administration).
Fasting blood glucose level in rabbits from group D was signiﬁcantly lower than in rabbits from group C at the 23rd
and 28th weeks.
FIGURE 6
Serum glucose and insulin during IVGTT carried out in overnight-fasted rabbits. There were no differences in blood glucose
(A) among the 4 groups during IVGTT carried out at week 0. However, blood glucose was signiﬁcantly higher in rabbits from
group C versus the rabbits from the other 3 groups at all time points, except at time 5 minutes, investigated after the glucose
injection at week 13 (B). After the intravenous glucose administration, serum insulin at time point 15 minutes (C) increased to a
higher extent in group B and group D, but in group C, plasma insulin at time point 15 minutes was signiﬁcantly lower than the
other 3 groups investigated at week 13. (Continued)32 W. YIN ET AL.
FIGURE 6
(Continued)
was signiﬁcantly lower than the other 3 groups investigated
at week 13. This indicated that high-fat/high-sucrose feeding
impaired the acute insulin response to the glucose challenge
in animals from group C and NO-1886 protected the acute
insulin response in animals from group D. This effect of the
compound was likely through reduced lipotoxicity.
Insulin Tolerance Test
Figure7showsbloodglucoselevelsafteranintraperitoneal
administration of insulin (0.75 units/kg body weight) in fed
animals at week 13. Insulin injection caused a decrease of
glucose levels with respect to basal glucose values by about
30% in group A, group B, and group D at 15, 30, and 60 min-
utes, whereas the decrease of blood glucose in group C was
signiﬁcantly lower. This suggests that NO-1886 improves in-
sulin sensitivity in high fat/high sucrose–fed rabbits.
DISCUSSION
It has previously been reported that NO-1886 increases
LPL activity in postheparin plasma, and produces a reduction
in plasma TG level with concomitant elevation of HDL-C
level in animals with lipid disorder [8–13]. However, thereNO-1886 IMPROVES GLUCOSE AND LIPID METABOLISM 33
FIGURE 7
Serum glucose levels after an intraperitoneal administration of insulin (0.75 units/kg body wt) in fed animals. Insulin injection
caused a decrease of glucose levels with respect to basal glucose values by about 30% in group A, group B, and group D at
15, 30, and 60 minutes, whereas the decrease of blood glucose in group C was signiﬁcantly less. Signiﬁcance:
¤P <: 05 versus group A. n D 3–4.
are few reports showing the effects of NO-1886 on glucose
metabolism. Hara and coworkers [15] demonstrated an ef-
fect of enhancing whole-body insulin sensitivity of NO-1886
supplementation. Kusunoki and colleagues [12] reported that
NO-1886suppressedaccumulationofvisceralfatandreduced
insulin resistance in high fat (safﬂower oil) feeding–induced
obesity type 2 diabetes animal model rats evaluated by eu-
glycemic hyperinsulinemic clamp [11]. It needs to be noted
that the above studies were generally short-term investiga-
tions and there were no intensive observations on the changes
of glucose levels. Recently, we used our own high fat/high
sucrose feeding–induced type 2 diabetes rabbits model [6] to
ascertain the effects of long-term administration of NO-1886
on atherosclerosis. By chance, we had an unexpected ﬁnding
that NO-1886 reduced blood glucose level in high fat/high
sucrose–fed rabbits [7]. However, the mechanism of plasma
glucose reduction by NO-1886 cannot be clearly explained
from the results of our previous study without performing the
glucose tolerance test or insulin tolerance test in our rabbit
model.
In the current study, we evaluated whole-body insulin sen-
sitivity using IVGTT and insulin tolerance test, and revealed
a signiﬁcant impact of NO-1886 supplementation on glucose
clearance and acute insulin response to intravenous glucose
loading in our mild diabetes rabbit model. This would in-
dicate a meaningful role of NO-1886 in suppressing post-
prandial blood glucose levels. Our results showed that in the
fasting state, the increase in glucose levels by feeding the
high-fat/high-sucrosedietwasinhibitedbysupplementing1%
NO-1886 into the high-fat/high-sucrose diet at the 8th week
time point (4 weeks after start of NO-1886 administration);
fasting blood glucose levels in NO-1886–supplemented high
fat/high sucrose–fed rabbits were signiﬁcantly lower than in
rabbits that were fed solely the high-fat/high-sucrose diet at
the 23rd and 28th weeks (Figure 5). However, we did not ob-
tain a signiﬁcant effect of NO-1886 on fasting insulin, so that
the decrease of fasting glucose would be due to improved in-
sulin sensitivity through the actions of NO-1886 on plasma
triglycerides and FFAs as shown in this study.
NO-1886 was primarily developed as a hypolipidemic
agent [8, 9]. It has been reported to increase lipoprotein li-
pase enzyme mass in postheparin plasma, causing a reduction
inplasmaTGlevel,withconcomitantelevationofHDL-C,by
increasing lipoprotein lipase activity in normal and diabetic
rats. Diabetes is associated with progressive development of
dyslipidemia, which is a risk factor for cardiovascular dis-
ease and arteriosclerosis, as well as a cause for lipotoxicity to
the liver, muscles, and pancreatic islets [1–3, 15–18]. It has
been well known that signiﬁcant elevations in plasma TG and
VLDL-C, and signiﬁcant reduction in HDL-C, appear to be
characteristicindiabeticpatients.However,presenttreatment
of diabetes by low-energy diets, oral hypoglycemic agents,
andinsulintherapyfrequentlyisnotsufﬁcientforperfectcon-
trol of lipid metabolism [16–19]. A drug, such as NO-1886,
that has a potential effect on dyslipidemia and beneﬁcial ac-
tions in glucose metabolism, as we demonstrated, would have34 W. YIN ET AL.
great implication in the treatment of diabetes and deserves
further studies. The high-fat/high-sucrose diet would have in-
duced lipotoxicity to the animals’ liver, muscles, and pan-
creatic islets that could have important inﬂuence on glucose
metabolism.TheknownactionsofNO-1886onlipoproteinli-
pase,plasmaTGlevel,andabdominalfataccumulationmight
account for the effects that we reported in the current study,
such as lowering blood glucose level, protecting the acute
insulin response to the glucose loading, and improving the
animal’s insulin sensitivity.
In summary, the results of the current study suggest that
NO-1886 suppress the elevation of blood glucose in rab-
bits induced by feeding a high-fat/high-sucrose diet probably
through controlling lipid metabolism and improving insulin
sensitivity.
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